$INM insider trading

Over the last 12 months, InMed Pharmaceuticals insiders reported 10 buys totaling $639K and no sales across SEC Form 4 filings.

$639K
—
10
2
0%
Side
$1$100$10K$1.0MAug '26SepOctNov
ADAR1 Capital Management, LLC
Vivo Opportunity, LLC

All insider trades

Scroll the table sideways for price, value and marks.

Oct 23, 2026ADAR1 Capital Management, LLC▲ Buy4$1.32$5—
Oct 19, 2026ADAR1 Capital Management, LLC▲ Buy1,087$1.32$1K+0.1%
Oct 15, 2026ADAR1 Capital Management, LLC▲ Buy9,569$1.33$13K+1%
Oct 8, 2026ADAR1 Capital Management, LLC▲ Buy10,903$1.33$14K+1.2%
Oct 5, 2026ADAR1 Capital Management, LLC▲ Buy42,920$1.33$57K+4.8%
Sep 16, 2026ADAR1 Capital Management, LLC▲ Buy91,101$1.3$118K+11.4%
Jul 16, 2026Vivo Opportunity, LLC▲ Buy20,546$1.55$32K+37.7%
Jul 15, 2026ADAR1 Capital Management, LLC▲ Buy1,000$1.56$2K+0.1%
Jul 2, 2026Vivo Opportunity, LLC▲ Buy6,551$1.55$10K+9.8%
Jun 8, 2026Vivo Opportunity, LLC▲ Buy249,227$1.57$392K—

Every $INM filing on this page is one API call away

The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? InMed Pharmaceuticals filings can reach your inbox instead.

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $INM feed.